Cancer Nursing Today Editors
The editors of Cancer Nursing Today are part of an experienced team of medical writers and researchers who report news and provide commentary related to oncology nursing.
Articles by Cancer Nursing Today Editors
Researchers used a centralized screening service to identify patients for participation in multiple myeloma clinical trials.
The recent study identified predictive factors associated with caregiver burden using six validated machine learning models.
A total of 389 patients were evaluated to understand the risk factors of BMI changes and AL ratio during induction therapy.
Less than one-third of eligible people within one regional academic health system had a screening test ordered.
Researchers hypothesized that earlier palliative care referral would mitigate patient symptom burden.
If a symptom was reported by a patient as moderate or severe, an algorithm-based system generated an alert notification.
The effectiveness of a multidomain intervention on patients' mental and physical health post-esophagectomy was explored.
Over 1,600 patients, with a median age of 66 years, participated in the global study from December 2021 to December 2024.
The study examined how obesity affected outcomes and healthcare use among more than 198,000 patients with endometrial cancer.
The program evaluated the practicality of independent pharmacists and nurses monitoring patients on a targeted-based regimen.
The analysis, presented at ASCO 2025, evaluated patient-reported outcomes and collected data on patient quality of life.
According to a team of researchers from China, family resilience could hold the key to boosting quality of life.
Understanding the relationship between caregiver burden and patient hope is essential, according to the researchers.
While RCC is the leading cause of cancer-related mortality, early detection can greatly improve disease outcomes.
Researchers investigated if a frailty index could assess for associations between toxicity, clinical outcomes, and frailty.
Research is currently limited on how GLP-1 receptor agonists affect ICI efficacy in patients with cancer.
The phase 3 study is the longest follow-up—9 years—of a first-line checkpoint inhibitor combination in advanced RCC.
Researchers predicted that sMAdCAM-1 could be used as a prognostic biomarker in ICI-based therapy for patients with mRCC.
Patients with ccRCC were randomly selected to receive pembrolizumab or placebo and categorized by risk for metastasis.
The study evaluated the effect of pretreatment emotional distress on OS among more than 3,000 patients with solid tumors.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.